Kalaris Therapeutics Inc(KLRS)

Biotechnology · Berkeley Heights, NJ

$2.76-0.07 (-2.47%)

Delayed quote: Oct 6, 2026, 3:59 PM EDT

Kalaris Therapeutics (KLRS) EV/FCF: History & Chart | TGMCharts

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T20:12:16.187Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:12:16.187Z.

Quote observation: 2026-10-06T19:59:41.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 60,243,977
Total debt · period ending 2026-06-30: 1,400,000
Cash · period ending 2026-06-30: 43,173,000
TTM free cash flow · period ending 2026-06-30: -45,633,000

FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KLRS EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

KLRS Competitors' EV/FCF Ratio

KLRS

Kalaris Therapeutics Inc

Current

Market Cap

$60.24M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GUTS

Fractyl Health, Inc.

vs KLRS

Market Cap

$60.42M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ONCY

Oncolytics Biotech Inc.

vs KLRS

Market Cap

$60.02M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XLO

Xilio Therapeutics, Inc.

vs KLRS

Market Cap

$59.18M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INKT

MiNK Therapeutics, Inc.

vs KLRS

Market Cap

$58.94M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs KLRS

Market Cap

$58.44M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACET

Adicet Bio, Inc.

vs KLRS

Market Cap

$58.43M

EV/FCF Ratio

N/A

TTM Avg

108.20x

3Y Avg

108.20x

5Y Avg

108.20x

RNXT

RenovoRx, Inc.

vs KLRS

Market Cap

$62.62M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BOLD

Boundless Bio, Inc.

vs KLRS

Market Cap

$57.76M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRTX

Heron Therapeutics, Inc.

vs KLRS

Market Cap

$62.78M

EV/FCF Ratio

N/A

TTM Avg

1.41x

3Y Avg

1.41x

5Y Avg

1.41x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Kalaris Therapeutics Inc (KLRS)	$60.24M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$60.42M	N/A	N/A	N/A	N/A
Oncolytics Biotech Inc. (ONCY)vs ›	$60.02M	N/A	N/A	N/A	N/A
Xilio Therapeutics, Inc. (XLO)vs ›	$59.18M	N/A	N/A	N/A	N/A
MiNK Therapeutics, Inc. (INKT)vs ›	$58.94M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$58.44M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$58.43M	N/A	108.20x	108.20x	108.20x
RenovoRx, Inc. (RNXT)vs ›	$62.62M	N/A	N/A	N/A	N/A
Boundless Bio, Inc. (BOLD)vs ›	$57.76M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$62.78M	N/A	1.41x	1.41x	1.41x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

KLRS EV/FCF Ratio Metrics

KLRS Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics